Professor Jiang Chen’s group at the School of Pharmacy of Fudan University has recently developed a biomimetic dendritic peptide nanoconjugate, which has the function of regulating the pro-inflammatory microenvironment of brain lesions and can be used in the early stage of Alzheimer’s disease (AD) Multi-target therapy provides new ideas for early treatment of AD
Researchers have found that due to the complexity of brain diseases, the disorder of the pro-inflammatory microenvironment in the brain is an important cause of AD.
In order to achieve multi-target treatment of the microenvironment of early AD lesions, based on the above microenvironment characteristics, Jiang Chen’s research group designed and constructed a dendritic peptide nanoconjugate that can simulate the transport of amyloid in the brain.
Related paper information: https://doi.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
